Leerink Partnrs Has Pessimistic View of BBIO FY2025 Earnings

BridgeBio Pharma, Inc. (NASDAQ:BBIO) – Equities research analysts at Leerink Partnrs cut their FY2025 earnings estimates for BridgeBio Pharma in a note issued to investors on Monday, July 14th. Leerink Partnrs analyst M. Foroohar now anticipates that the company will post earnings per share of ($2.99) for the year, down from their previous forecast of ($2.87). The consensus estimate for BridgeBio Pharma’s current full-year earnings is ($3.67) per share. Leerink Partnrs also issued estimates for BridgeBio Pharma’s FY2026 earnings at ($1.59) EPS and FY2027 earnings at $0.31 EPS.

BridgeBio Pharma (NASDAQ:BBIO) last announced its earnings results on Tuesday, April 29th. The company reported ($0.88) earnings per share for the quarter, beating the consensus estimate of ($1.00) by $0.12. The firm had revenue of $36.74 million during the quarter, compared to analysts’ expectations of $57.14 million. During the same period in the prior year, the company posted ($0.20) EPS. The company’s revenue was down 44.8% compared to the same quarter last year.

Several other brokerages also recently weighed in on BBIO. Redburn Atlantic started coverage on shares of BridgeBio Pharma in a research note on Monday, March 31st. They issued a “buy” rating and a $50.00 target price on the stock. Oppenheimer raised shares of BridgeBio Pharma from a “market perform” rating to an “outperform” rating and set a $60.00 target price on the stock in a research note on Wednesday, July 9th. JPMorgan Chase & Co. increased their target price on shares of BridgeBio Pharma from $44.00 to $50.00 and gave the company an “overweight” rating in a research note on Monday, March 24th. Wolfe Research started coverage on shares of BridgeBio Pharma in a research note on Tuesday, June 17th. They issued an “outperform” rating and a $49.00 target price on the stock. Finally, Piper Sandler increased their target price on shares of BridgeBio Pharma from $63.00 to $68.00 and gave the company an “overweight” rating in a research note on Monday. One equities research analyst has rated the stock with a hold rating and fifteen have issued a buy rating to the company. According to MarketBeat.com, BridgeBio Pharma has a consensus rating of “Moderate Buy” and a consensus price target of $61.20.

BridgeBio Pharma Trading Up 0.3%

Shares of BBIO opened at $47.10 on Wednesday. BridgeBio Pharma has a twelve month low of $21.72 and a twelve month high of $48.68. The company has a market cap of $8.94 billion, a P/E ratio of -13.34 and a beta of 1.15. The company’s fifty day simple moving average is $39.30 and its 200-day simple moving average is $35.65.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in BBIO. Capital Research Global Investors grew its position in shares of BridgeBio Pharma by 34.9% in the 4th quarter. Capital Research Global Investors now owns 3,526,747 shares of the company’s stock worth $96,774,000 after buying an additional 912,439 shares during the last quarter. Cambridge Investment Research Advisors Inc. grew its position in shares of BridgeBio Pharma by 29.4% in the 1st quarter. Cambridge Investment Research Advisors Inc. now owns 30,802 shares of the company’s stock worth $1,065,000 after buying an additional 6,997 shares during the last quarter. GAMMA Investing LLC grew its position in shares of BridgeBio Pharma by 71.0% in the 1st quarter. GAMMA Investing LLC now owns 920 shares of the company’s stock worth $32,000 after buying an additional 382 shares during the last quarter. Allspring Global Investments Holdings LLC purchased a new position in shares of BridgeBio Pharma in the 1st quarter worth approximately $251,000. Finally, Teacher Retirement System of Texas grew its position in shares of BridgeBio Pharma by 28.6% in the 4th quarter. Teacher Retirement System of Texas now owns 36,208 shares of the company’s stock worth $994,000 after buying an additional 8,048 shares during the last quarter. Hedge funds and other institutional investors own 99.85% of the company’s stock.

Insider Buying and Selling

In other BridgeBio Pharma news, Director Andrew Lo sold 100,000 shares of the firm’s stock in a transaction dated Friday, May 2nd. The shares were sold at an average price of $38.50, for a total transaction of $3,850,000.00. Following the transaction, the director owned 105,583 shares of the company’s stock, valued at approximately $4,064,945.50. This trade represents a 48.64% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, major shareholder Genetic Disorder L.P. Kkr sold 6,000,000 shares of the firm’s stock in a transaction dated Monday, May 12th. The shares were sold at an average price of $34.20, for a total transaction of $205,200,000.00. Following the transaction, the insider directly owned 13,260,971 shares in the company, valued at $453,525,208.20. This trade represents a 31.15% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 9,926,181 shares of company stock worth $375,528,164 over the last ninety days. 18.20% of the stock is owned by insiders.

About BridgeBio Pharma

BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.